Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHM7JS)

• Drug Name: Pasireotide Drug Info
• Synonyms: Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate; Signifor (TN); SOM 230; SOM-230

Indication

Disease Entry	ICD 11	Status	REF
Cushing disease	5A70	Approved	[1]

• Cross-matching ID:
  PubChem CID: 9941444
  ChEBI ID: CHEMBL3349607
  CAS Number: CAS 396091-73-9
  TTD Drug ID: DMHM7JS

Molecule-Related Drug Atlas

Drug(s) Targeting Somatostatin receptor type 3 (SSTR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[7]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[8]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[9]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[10]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[7]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[11]
Des-AA1,2,4,13-[D-Trp8]SRIF	DMR6Z2N	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Somatostatin receptor type 1 (SSTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lutetium Lu 177 dotatate	DMN1XVC	Neuroendocrine cancer	2B72.1	Approved	[12]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[7]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[8]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[9]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[10]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[7]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Somatostatin receptor type 2 (SSTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[13]
Lanreotide acetate	DMG6ZU4	Acromegaly	5A60.0	Approved	[14]
Ga-68-DOTATOC	DMZ0P95	Diagnostic imaging	N.A.	Approved	[15]
Copper dotatate Cu-64	DM26KR1	Diagnostic imaging	N.A.	Approved	[16]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
Paltusotine	DM97IN2	Acromegaly	5A60.0	Phase 3	[17]
TBR-760	DMM5BVG	Pituitary adenoma	2F37.0	Phase 2	[18]
Re-188-P-2045	DM614BA	Lung cancer	2C25.0	Phase 1/2	[19]
PEN-221	DMMAUOK	Neuroendocrine cancer	2B72.1	Phase 1/2	[20]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[21]

Drug(s) Targeting Somatostatin receptor type 5 (SSTR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[21]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[8]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[9]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[10]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[5]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[11]
Des-AA1,2,4,13-[D-Trp8]SRIF	DMR6Z2N	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor type 1 (SSTR1)	TTIND6G	SSR1_HUMAN	Inhibitor	[2]
Somatostatin receptor type 2 (SSTR2)	TTZ6T9E	SSR2_HUMAN	Inhibitor	[3]
Somatostatin receptor type 3 (SSTR3)	TTJX3UE	SSR3_HUMAN	Inhibitor	[4]
Somatostatin receptor type 5 (SSTR5)	TT2BC4G	SSR5_HUMAN	Inhibitor	[5]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).
• [6] Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
• [7] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [8] Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
• [9] Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
• [10] Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
• [11] An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
• [14] Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [17] Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
• [18] TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
• [19] The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.